<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3670">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348425</url>
  </required_header>
  <id_info>
    <org_study_id>11-003</org_study_id>
    <nct_id>NCT01348425</nct_id>
  </id_info>
  <brief_title>Zilver PTX Drug-Eluting Peripheral Stent Study</brief_title>
  <official_title>Evaluation of the Zilver PTX Drug-Eluting Peripheral Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cook</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cook</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <authority>Switzerland: Ethikkommission</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, post-market clinical study is intended to evaluate the delivery and
      deployment of longer Zilver PTX stents (≥ 100 mm) compared to shorter Zilver PTX stents (≤80
      mm) for treatment of lesions of the above-the-knee femoropopliteal artery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent Change in Stent Length Upon Deployment</measure>
    <time_frame>During Procedure (day 1) (Prior to Stent Deployment and after Stent Deployment)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Longer Stents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Shorter Stents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Longer Zilver PTX Stents</intervention_name>
    <description>Treatment with at least one 100 mm or longer Zilver PTX stent</description>
    <arm_group_label>Longer Stents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Shorter Zilver PTX Stents</intervention_name>
    <description>Treatment with Zilver PTX stents 80 mm or shorter only</description>
    <arm_group_label>Shorter Stents</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  One de novo or restenosed artherosclerotic lesion with &gt; 50% diameter stenosis

          -  Reference vessel diameter of 4 - 9 mm

          -  Rutherford category ≥ 2

          -  Resting ankle brachial index &lt; 0.9

        Exclusion Criteria:

          -  Prior stent in the study vessel

          -  Significant stenosis (&gt; 50%) or occlusion of inflow tract not successfully treated
             before the study procedure

          -  Lacks at least one patent runoff vessel

          -  Lesions requiring atherectomy, cutting balloons, cryoplasty balloons, or any other
             advanced device to facilitate stent delivery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Dr. med. Jens Ricke</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Magdeburg A.ö.R., Department for Radiology and Nuclear Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herz-Zentrum</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelische Krankenhaus Königin Elisabeth Herzberge</name>
      <address>
        <city>Berlin</city>
        <zip>10365</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg A.ö.R.</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INSELSPITAL, Universitätsspital Bern</name>
      <address>
        <city>Berne</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>December 29, 2015</lastchanged_date>
  <firstreceived_date>April 29, 2011</firstreceived_date>
  <firstreceived_results_date>July 25, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAD</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Longer Stents</title>
          <description>Longer Zilver PTX Stents : Treatment with at least one 100 mm or longer Zilver PTX stent</description>
        </group>
        <group group_id="P2">
          <title>Shorter Stents</title>
          <description>Shorter Zilver PTX Stents : Treatment with Zilver PTX stents 80 mm or shorter only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Imaging was not taken.</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Longer Stents</title>
          <description>Longer Zilver PTX Stents : Treatment with at least one 100 mm or longer Zilver PTX stent</description>
        </group>
        <group group_id="B2">
          <title>Shorter Stents</title>
          <description>Shorter Zilver PTX Stents : Treatment with Zilver PTX stents 80 mm or shorter only</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="45"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="67.6" spread="9.2"/>
                <measurement group_id="B2" value="71.6" spread="8.3"/>
                <measurement group_id="B3" value="68.8" spread="9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Stent Length Upon Deployment</title>
        <time_frame>During Procedure (day 1) (Prior to Stent Deployment and after Stent Deployment)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Longer Stents</title>
            <description>Longer Zilver PTX Stents : Treatment with at least one 100 mm or longer Zilver PTX stent</description>
          </group>
          <group group_id="O2">
            <title>Shorter Stents</title>
            <description>Shorter Zilver PTX Stents : Treatment with Zilver PTX stents 80 mm or shorter only</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="30"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change in Stent Length Upon Deployment</title>
            <units>Change in stent length (%)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" spread="4.2"/>
                  <measurement group_id="O2" value="-0.2" spread="3.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The alternative hypothesis is equivalence in mean change in stent length upon deployment between longer and shorter stents, i.e., the difference in mean change between the longer and shorter stents is close to 0. Thus, a small p-value indicates a 95% confidence interval covers 0.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>The equivalence margin is +/- 10%, type I error is assumed to be 0.05, with a power of 0.8.</non_inferiority_desc>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>Schuirman's TOST equivalence test on change in stent length upon deployment between longer and shorter stents.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>To test the hypothesis whether the percent change in stent length is contained within [-10%, 10%].</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.7</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Stented Patients</title>
          <description>The adverse events were combined because all patients were treated with Zilver PTX stents. The safety of Zilver PTX has been previously established and the primary objective of this study was changes in post-deployment stent length; i.e. immediately post-procedure.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal disease</sub_title>
                <description>failed hemodialysis shunt requiring revision (Due to a pre-existing condition.)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary disease</sub_title>
                <description>exacerbation of COPD (Due to a pre-existing condition.)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Orthopedic/vascular repair</sub_title>
                <description>lumbar protrusion (Due to other medical problems.)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Restenosis/occlusion of study lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Restenosis/occlusion of non-study limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott Snyder, PhD, Director of Clinical Science and Biostatistics</name_or_title>
      <organization>Cook</organization>
      <phone>765-463-7537</phone>
      <email>ssnyder@medinst.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
